re-labeled Pegylated nanoliposome as a radionuclide therapeutic agent in an orthotopic glioma-bearing rat model 
Introduction
Glioma is the most common primary tumor in the central nervous system. Glioblastoma multiforme (GBM), a World Health Organization (WHO) grade IV malignant glioma, accounts for more than half of total primary gliomas, with an average survival time ranging from 12 to 15 months. 1 High morbidity and mortality make glioma the fourth most serious malignant cancer. 2 The current standard treatment for GBM is essential surgical resection followed by a combination of radiation therapy plus adjuvant chemotherapy with temozolomide. 3, 4 Despite tremendous efforts on the treatments of Aside from surgery and chemotherapy, radiation therapy remains an important means of cancer treatment. Approximately 50% of all cancer patients are treated with radiation therapy with varying modalities including external beam, brachytherapy, and radionuclide therapy (RNT). 6 In the past decade, RNT has been increasingly adopted as a therapeutic radiopharmaceutical for treatment of cancers. In particular, radiation via RNT can be deposited to the lesion at the cellular level whereas conventional external beam therapy is limited to a gross anatomical level. 7 A wide variety of nanoparticles have been developed as drug carriers for treatment of cancers. Early clinical trials of some drug-incorporated nanoparticles have shown their efficacious cancer treatments owing to the passive accumulation of nanoparticles in the tumors by enhanced permeability and retention (EPR) effect and reducing the drug side effects to the system. 8 In recent years, radiolabeled nanoparticles such as 188 Re-lipid nanoparticles and 186 Re-liposome nanoparticles have been introduced for treatment of GBM via convection-enhanced delivery technique. [9] [10] [11] [12] These studies demonstrated that the survival of tumor-bearing rats was significantly prolonged with therapeutic radiopharmaceutical treatment. Although the convection-enhanced delivery technique affords apparent benefits for GBM treatment, it might still cause certain drawbacks in clinical practice. 13, 14 Moreover, the complicated drug delivery technique may not be ready and convenient for routine clinical uses. Therefore, development of a convenient and effective strategy for drug delivery is demanding for conducting RNT on GBM.
Systemic administration of therapeutic radiopharmaceuticals is an alternative but more feasible option of drug delivery for clinical RNT. Most recently, a new drug under investigation, 188 Re-labeled PEGylated nanoliposome ( 188 Re-liposome) has been successfully validated with a series of translational studies for treatment of colon cancer. [15] [16] [17] [18] [19] [20] Currently, it has also been approved by Department of Health, Taiwan for further human clinical trial for treatment of metastatic colon cancer (Phase I). According to our previous work, 188 Re-liposome had been explored in orthotopic glioma-bearing rat model for diagnostic evaluation where systemic administration was employed for delivering the radiolabeled liposome nanoparticles. 21 In this study, we aimed to evaluate the therapeutic efficacy of 188 Re-liposome for GBM in orthotopic glioma-bearing rat model where single intravenous injection of 188 Re-liposome was employed.
188
Re, a VII B family element in the periodic table, has a similar physicochemical property to 99m Tc. It exhibits a physical half-life of 16.9 hours. Specifically, it emits not only a diagnostic gamma ray (E γ =155 KeV) but also a therapeutic beta radiation (E βmax =2.1 MeV). 22 In order to prove our concept for treatment of GBM tumor by 188 Reliposome via single intravenous injection, the related serial experiments including establishment of luciferase expressing reporter cell (F98 luc ), maximum tolerated dose (MTD), bioluminescent imaging (BLI), radiation dosimetry (OLINDA/ EXM), therapeutic efficacy, and so forth, were performed in this study.
Materials and methods Materials
Lentivector expression kit system was obtained from System Biosciences (SBI) (Mountain View, CA, USA) and XenoLight D -Luciferin potassium salt was from PerkinElmer Inc.
® (Waltham, MA, USA). Distearoylphosphatidylcholine (DSPC), cholesterol and polyethylene glycol (MW ~2 kDa) -derived distearoylphosphatidylethanolamine (DSPE-PEG 2000 ) were purchased from Genzyme (Cambridge, MA, USA). Cell culture materials were purchased from GIBCO™ BRL (Grand Island, NY, USA). PD-10 column was purchased from GE Healthcare BioSciences AB (Uppsala, Sweden). N,N-bis(2-mercaptoethyl)-N′,N′-diethylethylenediamine (BMEDA) was from ABX (Radeberg, Germany). Hematoxylin and eosin (H and E) staining agents were from Sigma-Aldrich Co. (St Louis, MO, USA). Zoletil ® 50 anesthetic was from Virbac (Virbac Taiwan Co., Ltd., Taiwan). All other chemicals were from Merck (Darmstadt, Germany).
cell culture and cell growth curve
The F98 glioma cell line was kindly provided by Dr JengJong Hwang of National Yang Ming University, Taipei, Taiwan, which was originally produced by Dr Rolf F Barth of Ohio State University, Cincinnati, Ohio, USA. 23 This cell line was transfected with the luciferase gene to express luciferase as reporter (F98 luc ) through Lentivector expression kit and the F98 luc cells were sorted via green fluorescent protein (GFP) by a fluorescence-activated cell sorter (BD FACSAria™ III, San Jose, CA, USA). The F98 luc cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum, 100 units/mL penicillin, and 100 μM/mL streptomycin. Cells were incubated at 37°C in a humidified environment with 5% CO 2 . The rats (male, 12-13 weeks old) were anesthetized with isoflurane ® and then administered atropine sulfate (0.1 mg/kg) via subcutaneous injection; subsequently, the rats were deeply anesthetized by intraperitoneal injection of Zoletil ® 50 and Balanzine 2% mixture at a 5:2 volume ratio (0.1 mL/100 g rat body weight). After anesthesia, the hair on the rat's head was removed from the operative field. Then, the rats were immobilized by a stereotactic frame (Stoelting ® , Wood Dale, IL, USA). A 2 cm linear incision was carefully made and the immobilized for the following surgery. After removing the periosteum, a 1 mm diameter hole was created with a highspeed drill in the skull of the right brain (located at 3 mm lateral to midline and 5 mm anterior to lambda) and the dura carefully pricked with sharp tweezers. For implantation, the F98 luc cells were harvested and re-suspended in Hank's balanced salt solution plating on the ice before use. The 1×10 5 cells in 10 μL medium were inoculated into the brain (a depth of 5 mm from the skull bone) using a 100 μL Hamilton ® syringe and 27-1/2 gauge needle through nanoliter syringe pump (KDS 310 plus; Holliston, MA, USA) with the injection rate of 3 μL/min. After seeding, the needle was retained for 2 minutes and then drawn out carefully and slowly. Finally, paraffin was used to fill the surgical hole and the incision was sutured. The rats were observed closely until completely awake.
BlI
The BLI was performed by IVIS™ Imaging System 100 Series (Xenogen ® , USA). The imaging protocol was in accordance with that previously described, but with some modifications. 26, 27 For in vitro imaging, F98 luc cells were diluted from 100,000 to 195 cells by culture medium and each group of cells (in 100 μL) was carefully loaded into a black 96-well plate. Then, the D -Luciferin substrate (in medium) was added to each well at a concentration of 150 μg/mL for 5 minutes incubation and the cells-loaded plate was imaged continuously for 1 minute with the IVIS™ system. For in vivo imaging, the tumor bearing rats were administered D -Luciferin substrate in PBS (75 mg/kg) via intraperitoneal injection. At 15 minutes post-injection, the rats were anesthetized with 3% isoflurane and then imaged continuously for 10 minutes with the IVIS™ system. To monitor Fischer344/F98 luc tumor growth curve in a relationship between bioluminescent intensity and time, the tumor bearing rats were imaged from Day 3 to Day 13 post-inoculation, respectively. After Day 13 imaging, the rats were sacrificed by CO 2 euthanasia and the brain tumor was dissected for histopathological examination (H and E staining). Tumoral luminescence intensity (photon/s) was quantified by conducting a region of interest assay using the Living Image software (Xenogen ® ).
Preparation of neutral Pegylated nanoliposomes
The lipid film hydration-extrusion combining repeated freeze-thawing method was used to prepare neutral PEGylated nanoliposomes as previously reported. 28 Briefly, the mixture of DSPC: cholesterol: DSPE-PEG 2000 at the molar ratio of 3:2:0.3 was dissolved in chloroform followed by removing the solvent with rotary evaporation. Then the 250 mM ammonium sulfate at pH 5.5 was used to rehydrate the dry lipid film at 60°C. After rehydration, the liposomes were extruded three times through polycarbonate membrane filters with varying pore sizes at 0.4, 0.2, 0.1, 0.05, and 0.03 μm, respectively (Sterlitech Corp., Kent, WA, USA) by a high-pressure extruder (LIPEX™, Northern Lipids Inc., Burnaby, BC, Canada). Finally, normal saline was introduced to replace extraliposomal buffer via elution through a Sephadex G-50 column (Pharmacia, Uppsala, Sweden). The size and the zeta potential of the nanoliposomes were analyzed by a dynamic light scattering analyzer (N4 plus; Beckman Coulter Inc., CA, USA). Phospholipid concentration was measured via phosphorus assay with ultraviolet-visible spectrophotometry at λ=830 nm (JascoV-530, Tokyo, Japan). Re-liposome preparation, the preformed PEGylated nanoliposomes and 188 Re-BMEDA complex were added together into a vial at a volume ratio of 1:1 (1 mL:1 mL) and capped with rubber septum and aluminum foil. Then the solution mixture was incubated in a 60°C water bath shaking at 100 rpm for 30 minutes. After reaction, the preparation vial was taken out and cooled down at room temperature for 10 minutes. Subsequently, a PD-10 size exclusion column was utilized to purify 188 Re-liposome from 188 Re-BMEDA complex and free rhenium-188 (Na 188 ReO 4 ) via elution with normal saline. Each 0.5 mL eluate was collected in an Eppendorf tube and the liposome opacity was visualized to monitor the position of 188 Re-liposome. The radiochemical yield was calculated by the radioactivity of the collected product divided by the total initial loaded radioactivity for the separation.
MTD of 188 re-liposome in Fischer344 rats
The MTD of medication in animal trial was defined as the radioactivity dose below the dose resulting in either the death of any animal in groups of five animals or body weight loss of more than 20%. 17, 31 To obtain the MTD for referring therapeutic evaluation, the toxicity of 188 Reliposome in Fischer344 rats was estimated. First, fifteen normal male Fischer344 rats (12-13 weeks old) were randomly divided into three groups (five rats per group) and administered 188 Re-Liposome (2.5 μmol phospholipids/ 0.5 mL) at dosage of 296, 333, and 370 MBq via single intravenous injection for respective groups. After medication, the body weight loss of rats of each group was recorded twice per week for 1 month and the lethality of radiation toxicity in rats was monitored every day for 1 month.
radiation dosimetry estimation
Internal radiation-dose assessment of 188 Re-liposome in nuclear medicine was simulated using OLINDA/EXM 1.1 computer software according to previous reports. 26, 32, 33 In order to evaluate the equivalent dose (Sv) in humans, the relative organ-mass scaling method was used. Before starting computer calculation, the bio-distribution of 188 Re-liposome in human (73 kg adult) organs was extrapolated from our previous results of percentage injected activity per gram for the organ (%IA/g organ ) in rats 21 and then calculated according to the following formula:
The extrapolated bio-distribution data (%IA/organ) of 188 Re-liposome in human organs at 1, 4, 24, 48, and 72 hours were entered into OLINDA/EXM 1.1 software. The integral (MBq ⋅ s) information from selected 14 organs including heart contents (blood), muscle, testes, pancreas, stomach, small intestine, large intestine, kidney, spleen, liver, lung, heart, brain, and remainder of the body, was used to evaluate radiation dosimetry. The activity of remainder of the body was defined as the total activity in the body minus all of the activities from selected organs. In addition, the distribution of activity of remainder of the body was presumed to be uniform. To estimate tumoral absorbed dose (Gy) at different tumor sizes ranging from 0.01 to 6,000 g, the sphere model in OLINDA/EXM 1.1 software was used. The uptake value of tumor (%IA/g) in biodistribution study in rats 21 was directly entered into OLINDA/ EXM 1.1 software prgram for dosimetry estimation.
Therapeutic efficacy evaluation
To evaluate therapeutic efficacy of 188 Re-Liposome in Fischer344/F98 luc orthotopic glioma bearing rat model, a total of 35 rats was used herein. For survival evaluation study, 14 tumor bearing rats were randomly divided into two groups (seven rats per group). Subsequently, the rats of two groups were administered normal saline (control group) and 188 Re-liposome (333 MBq/0.5 mL; 2.5 μmol phospholipid/0.5 mL) via single intravenous injection on Day 7 post-inoculation, respectively. Then the rats were monitored for survival and body weight every day until death. In addition, a decrease in body weight of 20% or more compared with weight on the day of inoculation was considered as a humane endpoint for survival evaluation. For tumor-growth inhibition study, 21 tumor bearing rats were used. Nine rats per group were administered saline (control group) and 188 Re-liposome (333 MBq/0.5 mL; 2.5 μmol phospholipids/0.5 mL) via single intravenous injection on Day 7 post-inoculation, respectively. Then, three rats from each group were randomly sacrificed with CO 2 euthanasia on Day 10, 14, and 17 post-inoculation, respectively (another 3 rats were sacrificed on Day 6 post-inoculation). The brain tumors were carefully dissected, measured, and weighed. The tumor volume (mm 
. Meanwhile, the histopathological examination of the tumors was performed on Day 14 post-inoculation by staining with H and E according to routine staining protocol.
statistical analysis
All data were expressed as mean ± standard error of the mean (SEM). The unpaired Student's t-test was used for group comparisons. For therapeutic efficacy evaluation studies, survival curves were compared by use of the logrank test (SPSS software; SPSS Inc., Chicago, IL, USA). Values of P,0.05 were considered significant.
Results

Bioluminescence of F98 luc cell line and in vitro growth curve
After sorting via GFP by FACS, the purity of luciferase-expressed F98 luc cells was greater than 95%. The luminescence emission of F98 luc cells was detected using BLI technique as shown in Figure 1A . The minimal amount of cells for effective detection using BLI device was approximately 195 cells per well. In addition, the intensity of bioluminescence was highly correlated with the total amount of F98 luc cells with the linear correlation coefficient between bioluminescent intensity and cell numbers fitted R 2 =0.99 ( Figure 1C ). The in vitro growth curve of F98 luc cells is shown in Figure 1B . The T d of F98 luc cells was calculated to be 26.23 hours.
In vivo monitoring of Fischer344/F98 luc tumor growth
For monitoring brain tumor growth in vivo, the noninvasive images of tumor growth were acquired from Fischer344/F98 luc glioma-bearing rat model via BLI device at different time intervals ( Figure 2A ). The intensity of bioluminescence from tumor region was apparently enhanced as the time of post-inoculation increased. To understand the accurate trend of tumor growth curve, the quantitative region of interest analysis from bioluminescent images was carried out ( Figure 2B ). The tumor growth curve indicates that intensity of bioluminescence increased slowly and reached a plateau on Day 13 after inoculation. Furthermore, the histopathological analysis of tumor parenchyma on Day 13 after inoculation shows that the phenomenon of central necrosis was observed in the tumor ( Figure 2C ).
characterizations of Pegylated liposome and 188
re-liposome (less than 20% changes) at first and then the body weight gradually recovered to normal after Day 7 post-injection. However, one rat died after receiving 370 MBq treatment. Given the above experimental data, the MTD value for therapeutic evaluation with 188 Re-liposome in the Fischer344 rats was estimated to be 333 MBq. Note: *The OlINDa/eXM 1.1 software was applied in the radiation dosimetry with equivalent doses estimated for a 73 kg male adult. Abbreviations: llI, lower large intestine; UlI, upper large intestine. radiation dosimetry Table 1 shows the organ equivalent dose estimation of   188 Re-liposome for humans via orthotopic glioma-bearing rat model. The high equivalent doses were found in the spleen (6.96 mSv/MBq) and the kidneys (1.2 mSv/MBq). Moderate equivalent doses were observed in the heart wall (0.89 mSv/MBq), liver (0.81 mSv/MBq), lung (0.43 mSv/MBq), small intestine (0.2 mSv/MBq), lower large intestine (0.14 mSv/MBq), pancreas (0.13 mSv/MBq), and stomach wall (0.12 mSv/MBq) etc. Slight equivalent doses were found in the normal brain (0.02 mSv/ MBq), red marrow (0.05 mSv/MBq) and thyroid (0.07 mSv/ MBq) and so forth. In addition, the tumoral absorbed doses were estimated to be 122 to 13.6 mGy/MBq corresponding to the tumor sizes of 1 to 10 g, respectively.
Post-injection time (d) % of original body weight
Therapeutic efficacy Figure 4 shows the survival curves for 188 Re-liposome and normal saline treatment on a Fischer344/F98 luc glioma-bearing rat model. The result shows that the lifespan for the 188 Re-liposometreated group was significantly increased by 10.67% compared to control group (P=0.007). The statistical analysis for therapeutic efficacy evaluation is summarized in Table 2 . The maximum survival time for the 188 Re-liposome-treated group and control group was 24 and 19 days, respectively. In addition, the median survival time was 20.75 and 18.75 days, respectively.
To monitor tumor growth inhibition, the treated rats were euthanized at predetermined times and the tumor masses (Figure 5D ).
Discussion
The bio-distribution, pharmacokinetics, and imaging of 188 Re-liposome in the orthotopic glioma-bearing rat model have been studied in our recent report. 21 Previous work revealed that 188 Re-liposome is retained in the GBM tumor area with approximately 2 %ID/g with T/N (tumor-to-normal 
471
188 re-liposome as a therapeutic agent in glioma rat model brain) uptake ratio as high as 32.5 at 24 hours post-injection. To elucidate the mechanism underlying the significant accumulation of injected 188 Re-liposome in a tumor, it is presumed that 188 Re-liposome (~80 nm) can cross leaky blood-brain barrier (BBB) near the glioma followed by retention in the tumor parenchyma by EPR effect. Leaky BBB structure in the Fischer344/F98 rat has also been confirmed via immunohistochemistry assay of the brain. 34 Moreover, as previously reported, the neutral, negatively-charged, and/or PEGylated liposome may display larger retention volume in the brain than positive charged/unshielded liposome. 35 The critical exclusion size of the endothelial gap in human primary GBM (U87 MG cell line) was estimated to be 7-100 nm, which may allow the passage of the 80 nm sized 188 Re-liposome nanoparticles. 36 Based on the aforementioned substantial evaluation, 188 Re-liposome is worthy of further development as a therapeutic agent in orthotopic glioma-bearing rat model via single intravenous injection as discussed in this study.
In order to determine the appropriate treatment dose of 188
Re-liposome in glioma rat model, the MTD estimation of 188 Re-liposome in normal Fischer344 rats was conducted before the therapeutic experiments. According to the related studies in the previous reports, the acute toxicity of 188 Reliposome in rats was estimated as the following. 37, 38 The rats administered 185 MBq 188 Re-liposome only, via intravenous injection, showed slight body weight loss (without causing any death) until 1 month. In this study, three higher dosages (296, 333, and 370 MBq) of
188 Re-liposome were tested separately for the MTD estimation experiment. The results showed none of the rats in each group lost body weight over 20% in the period of 1 month after injection except for one rat which died in the group with the highest dosage (370 MBq). From the above experiment, the MTD of 188 Re-liposome for Fischer344 rats was estimated to be 333 MBq.
For BLI experiments, the F98 cells expressing luciferase were successfully constructed by lentiviral-mediated transfection. By suspending a serial number of F98 luc cells in the 96-well plate, the in vitro BLI showed a good linear relationship (R=0.99) between the cell number and the photo intensity ( Figure 1C) ; meanwhile, the minimum detectable bioluminescent signal was shown to locate at the cell number 195. These results are comparable to those reported in the literature. 27 As shown in the BLI study, the GBM tumor images can be clearly displayed via F98 luc reporter at different time points after inoculation; meanwhile, the tumor growth could be monitored by the intensity of bioluminescence. In vivo monitoring by BLI declared that the tumor growth in orthotopic Fischer344/F98 luc model rose gradually until Day 13 post-inoculation and then plateaued ( Figure 2B ). The presentation of the plateau could reveal the phenomena as follows. First, the larger tumor size (.10 mm) could have shielded some extent of the bioluminescence. Second, the tumoral central core could have had areas of necrosis with hypoxia which would cause decreased expression of luciferase. 39 The imaging information of in vivo BLI in Fischer344/F98 luc model is in good compliance with a previous report in the literature. 40 In short, the well-established Fischer344/F98 luc model can provide convenient, rapid, and non-invasive monitoring of the orthotopic tumor growth.
The lifespan of the glioma-bearing rats treated with 188
Reliposome was found to have 10.67% prolongation compared to control group (P,0.05). In addition, the tumor volume or tumor weight monitoring after treatments displayed significant difference (P,0.05) between the 188 Re-liposome-treated and control group. Although only ~2 %ID/g 188 Re-liposome was retained in the tumor area, 21 the dosage of 333 MBq was sufficient to damage the cancer cells, resulting in prolongation of the lifespan of the rats. Once 188 Re-liposome was accumulated in the tumor area by EPR effect, the beta particle radiation emitted from 188 Re could powerfully damage the surrounding tumor cells, even spreading to the cells in the vicinity (.1 cm) . This wide range of killing tumor capability by emitted β ray or electrons is known as "cross fire" effect, 41 by destroying a tumor without necessarily targeting every cell within the tumor. Moreover, the cross fire effect may compensate for the insufficient extent for heterogeneous tumor uptake. 42 In combination with chemotherapy, 188 Re-liposome could be further incorporated with doxorubicin or other drugs to multiply the therapeutic efficacy. 43 Moreover, further modifications of liposome surface with lactoferrin may be beneficial for its trafficking across BBB, which may further improve the therapeutic efficacy. 28 All of these novel designs would be added in our future work for developing the radio-labeled liposome system as a potential therapeutic agent for GBM for clinical use.
Conclusion
In this study, the MTD of 188 Re-liposome is worthy for further development as a potential diagnostic agent of RNT against GBM.
